HBV-IN-52

HBV-IN-52 is a selective HBV inhibitor. HBV-IN-52 is a Neplanocin A (HY-130430) derivative that demonstrates significant activity against HBV replication with EC50 = 0.96 μM. HBV-IN-52 can inhibit HBsAg secretion (EC50 = 0.82 μM. HBV-IN-52 can be studied in research for chronic hepatitis B (CHB) infections[1].

Product Specifications

UNSPSC

12352005

Target

HBV

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

OCC1=C[C@@H](N2N=C(I)C3=C2N=CN=C3C)[C@H](O)[C@@H]1O

Molecular Formula

C12H13IN4O3

Molecular Weight

388.16

References & Citations

[1]Kasula M, et al., Pyrazolo[3,4-d]pyrimidine-based neplanocin analogues identified as potential de novo pharmacophores for dual-target HBV inhibition. RSC Med Chem. 2025 Feb 20.